{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:33Z","timestamp":1786986873687,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.clinthera.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T19:16:48Z","timestamp":1320434208000},"page":"1560-1576","source":"Crossref","is-referenced-by-count":30,"title":["Eltrombopag: An Oral Thrombopoietin Receptor Agonist for the Treatment of Idiopathic Thrombocytopenic Purpura"],"prefix":"10.1016","volume":"33","author":[{"given":"Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.10.004_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2011.10.004_bib2","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1345\/aph.1P042","article-title":"Eltrombopag: a novel oral thrombopoietin receptor agonist","volume":"44","author":"Corman","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2011.10.004_bib3","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib4","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/j.1538-7836.2006.02147.x","article-title":"Prevalence of immune thrombocytopenia: analyses of administrative data","volume":"4","author":"Segal","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2011.10.004_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.10.004_bib6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0002-9343(99)80342-8","article-title":"Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2011.10.004_bib7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(01)07219-1","article-title":"Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study","volume":"358","author":"Kuhne","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.004_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0140-6736(09)60255-5","article-title":"New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura","volume":"373","author":"Nurden","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.004_bib10","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.med.60.042307.181154","article-title":"Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia","volume":"60","author":"Kuter","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2011.10.004_bib12","first-page":"3118","article-title":"Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer","volume":"89","author":"Basser","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib13","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199702063360603","article-title":"Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer","volume":"336","author":"Fanucchi","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.10.004_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood.V100.2.728","article-title":"Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura","volume":"100","author":"Nomura","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib15","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1592\/phco.30.7.666","article-title":"Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag","volume":"30","author":"Chouhan","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2011.10.004_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1078155209337668","article-title":"Review article: Second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults","volume":"16","author":"Lam","year":"2010","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.clinthera.2011.10.004_bib18","series-title":"PROMACTA (eltrombopag) [prescribing information]","year":"2009"},{"key":"10.1016\/j.clinthera.2011.10.004_bib19","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib20","doi-asserted-by":"crossref","first-page":"14253","DOI":"10.1074\/jbc.M611616200","article-title":"NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains","volume":"282","author":"Kim","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clinthera.2011.10.004_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-1-4419-7073-2_17","article-title":"Eltrombopag","volume":"157","author":"Bussel","year":"2011","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clinthera.2011.10.004_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.clinthera.2011.10.004_bib23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.exphem.2009.06.011","article-title":"Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function","volume":"37","author":"Erhardt","year":"2009","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib24","doi-asserted-by":"crossref","first-page":"568a","DOI":"10.1182\/blood.V104.11.2063.2063","article-title":"Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agnoist, in chimpanzees, rats and dogs","volume":"104","author":"Sellers","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2010.04.002","article-title":"Thrombopoietic agents","volume":"24","author":"Stasi","year":"2010","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2011.10.004_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0014-5793(95)01072-M","article-title":"Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro","volume":"374","author":"Ezumi","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clinthera.2011.10.004_bib28","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1055\/s-0038-1649979","article-title":"Modulation of platelet activation in vitro by thrombopoietin","volume":"74","author":"Kojima","year":"1995","journal-title":"Thromb Haemost"},{"issue":"Pt 1","key":"10.1016\/j.clinthera.2011.10.004_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj3160093","article-title":"Thrombopoietin potentiates activation of human platelets in association with JAK2 and TYK2 phosphorylation","volume":"316","author":"Rodriguez-Linares","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.clinthera.2011.10.004_bib30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0091270010375427","article-title":"Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura","volume":"51","author":"Gibiansky","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0091270010368677","article-title":"Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers","volume":"51","author":"Matthys","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.004_bib33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1177\/0091270010383019","article-title":"Population PK\/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing","volume":"51","author":"Hayes","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib34","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2133\/dmpk.DMPK-10-SC-051","article-title":"Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations","volume":"25","author":"Lim","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2011.10.004_bib35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000209851","article-title":"UGT1A1 haplotype mutation among Asians in Singapore","volume":"96","author":"Zhou","year":"2009","journal-title":"Neonatology"},{"key":"10.1016\/j.clinthera.2011.10.004_bib36","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","article-title":"Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients","volume":"98","author":"Jada","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clinthera.2011.10.004_bib37","series-title":"Abstract presented at: 18th Population Approach Group in Europe (PAGE)","article-title":"Use of eltrombopag exposure-platelet response relationship for dose optimization in patients with chronic HCV infection with and without interferon","author":"Zhang","year":"2009"},{"key":"10.1016\/j.clinthera.2011.10.004_bib38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0091270010372106","article-title":"Effect of hepatic or renal impairment on eltrombopag pharmacokinetics","volume":"51","author":"Bauman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2009.04.010","article-title":"Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies","volume":"31","author":"Williams","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2011.10.004_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00228-009-0716-6","article-title":"Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis","volume":"66","author":"Jenkins","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib41","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.10.004_bib42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.10.004_bib43","first-page":"285","article-title":"Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study","volume":"114","author":"Saleh","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib44","first-page":"1176","article-title":"Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura","volume":"112","author":"Bussel","year":"2008","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2011.10.004_bib45","article-title":"Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura (Itp)","volume":"93","author":"Psaila","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2011.10.004_bib46","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cld.2009.05.012","article-title":"Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C","volume":"13","author":"Dusheiko","year":"2009","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinthera.2011.10.004_bib48","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"issue":"1 Suppl 2","key":"10.1016\/j.clinthera.2011.10.004_bib49","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminhematol.2008.12.007","article-title":"Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents","volume":"46","author":"Vadhan-Raj","year":"2009","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib50","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2011.10.004_bib51","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.seminhematol.2010.02.006","article-title":"Thrombocytopenia in patients with myelodysplastic syndromes","volume":"47","author":"Bryan","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2010.45","article-title":"Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP","volume":"24","author":"Koehrer","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2011.10.004_bib53","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2010.02.005","article-title":"Reduced proliferation of non-megakaryocytic acute myelogenous leukemia and other leukemia and lymphoma cell lines in response to eltrombopag","volume":"34","author":"Erickson-Miller","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2011.10.004_bib54","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.leukres.2010.06.029","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome","volume":"35","author":"Mavroudi","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2011.10.004_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157488610790936196","article-title":"Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia","volume":"5","author":"Cuker","year":"2010","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clinthera.2011.10.004_bib57","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V87.5.1833.1833","article-title":"Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates","volume":"87","author":"Harker","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2011.10.004_bib58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0781.2010.00538.x","article-title":"Eltrombopag (75 mg) does not induce photosensitivity: results of a clinical pharmacology trial","volume":"26","author":"Bowen","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.clinthera.2011.10.004_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2125.2010.03646.x","article-title":"Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects","volume":"70","author":"Matthys","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2011.10.004_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MJT.0b013e318199d6b7","article-title":"Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations","volume":"17","author":"Serebruany","year":"2010","journal-title":"Am J Ther"},{"issue":"2 Suppl 2","key":"10.1016\/j.clinthera.2011.10.004_bib62","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2146\/ajhp080493","article-title":"New options after first-line therapy for chronic immune thrombocytopenic purpura","volume":"66","author":"Burzynski","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2011.10.004_bib63","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811006758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811006758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T23:34:59Z","timestamp":1593214499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811006758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0149291811006758"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.10.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}